Our genome-wide analysis highlights the complex crosstalk between these two transcription factors and sets the stage for a better understanding of the biological synergy that may underlie the protective effects of both E2 and cAMP signaling against apoptosis and of high CREB1 levels in breast cancer patients. This evidence concerns the gene CREB1 and breast carcinoma.